A Phase II Trial of Panobinostat in Patients With Gastrointestinal Neuroendocrine Tumors.
Phase of Trial: Phase II
Latest Information Update: 19 Jul 2017
At a glance
- Drugs Panobinostat (Primary)
- Indications Neuroendocrine carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 19 Jun 2017 Status changed from completed to discontinued.
- 10 Jun 2017 Biomarkers information updated
- 29 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.